C-8TN3General Control
epigenetic editing, gene activation, programmable therapies
editinggene editing
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-8TN3
C-8TN3C-8TN3epigenetic editing, gene activation, programmable therapies
0-100 chain-logic scale · 15 dimensions · scored on public evidence
General Control epigenetic editing, gene activation, programmable therapies
General Control develops programmable therapies intended to rewrite the expression of multiple genes at once. Its stated focus is multiplexed epigenetic editors for coordinated, locus-specific control of disease-network nodes in age-related diseases such as Alzheimer’s and sarcopenia. The site mentions a platform partnership with Novo Nordisk to develop next-generation therapies using programmable epigenetic gene activation.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
General Control — Far from goals · Bottom quartile. Derived deterministically from 6 extracted project(s). Most-advanced status: exploratory. Band: far. Modifiers: +5 depth (3 programs at exploratory).…
Source: Deterministic